CorVista Health Demonstrates High-Sensitivity for Noninvasive Detection of CAD including INOCA (Ischemia with No Obstructed Coronary Arteries) at ACC.26 CorVista Health, a leader in noninvasive cardiovascular diagnostics, announced new data evaluating a physiologic signal–based machine-learning model for detecting cardiac ischemia.…
Quince Therapeutics Settles Approximately $16.4 Million of Debt Quince Therapeutics, Inc. announced the successful settlement of the company’s outstanding obligations under its loan from the European Investment Bank (EIB) for a payment of $5.5 million. This marks a material milestone…
Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right Aurinia Pharmaceuticals Inc. a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs, announced…
TruArc Partners Acquires North American Adhesives and Sealant Solutions Provider Matrix Adhesives Group TruArc Partners a private equity firm focused on middle-market investments in business services and specialty manufacturing, announced today that it has acquired Matrix Adhesives Group (“Matrix” or…
Ditch Technology Secures Patent on Behavior Based Marine Routing; Offers OEMs a Production Ready Path to a Smarter Helm. Ditch Technology Inc. announced it has secured US Patent No. 12,429,339 for behavior based marine routing and is making its production…
LIB Therapeutics Announces Results from Presentations on LEROCHOL® at 2026 American College of Cardiology meeting in New Orleans March 28-29, 2026 LIB Therapeutics Inc. a privately-held, biopharmaceutical company with a recently approved novel, monthly, small dose third-generation PCSK9 inhibitor, LEROCHOL® (lerodalcibep-liga), announced…
Kardigan Announces Positive Phase 2 Data for Tonlamarsen in Patients with Uncontrolled Hypertension Presented as Late-Breaker at ACC.26 and Simultaneously Published in JACC Kardigan™, a clinical-stage precision therapeutics company developing medicines that target the root cause of specific cardiovascular diseases…
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting Incyte announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor,…
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care Takeda announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2…
Corcept Presents Data from MOMENTUM Trial at American College of Cardiology Annual Scientific Session Corcept Therapeutics Incorporated a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the…
Anumana Secures FDA Clearance for First-of-Its-Kind ECG-AI Algorithm for Early Detection of Pulmonary Hypertension Anumana, a leader in cardiovascular AI, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its pulmonary hypertension (PH) algorithm, an AI-enabled software-as-a-medical-device (SaMD)…
Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology’s 75th Annual Scientific Session and Expo Arrowhead Pharmaceuticals, Inc. announced long-term efficacy and safety data from a two-year long…